vs
阿普塔集团（ATR）与ICU MEDICAL INC（ICUI）财务数据对比。点击上方公司名可切换其他公司
阿普塔集团的季度营收约是ICU MEDICAL INC的1.8倍（$982.9M vs $540.7M），阿普塔集团净利率更高（7.4% vs -2.9%，领先10.3%），阿普塔集团同比增速更快（10.8% vs -14.1%），阿普塔集团自由现金流更多（$53.3M vs $36.0M），过去两年阿普塔集团的营收复合增速更高（3.9% vs -2.3%）
阿普塔集团（AptarGroup, Inc.）是总部位于美国的全球性制造企业，主营消费品分配包装产品及药物给药装置的研发与生产，目前在全球18个国家设有生产运营基地，服务医药、快消等多领域客户。
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
ATR vs ICUI — 直观对比
营收规模更大
ATR
是对方的1.8倍
$540.7M
营收增速更快
ATR
高出24.9%
-14.1%
净利率更高
ATR
高出10.3%
-2.9%
自由现金流更多
ATR
多$17.3M
$36.0M
两年增速更快
ATR
近两年复合增速
-2.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $982.9M | $540.7M |
| 净利润 | $72.8M | $-15.7M |
| 毛利率 | — | 37.5% |
| 营业利润率 | 10.9% | 1.0% |
| 净利率 | 7.4% | -2.9% |
| 营收同比 | 10.8% | -14.1% |
| 净利润同比 | -7.5% | 34.0% |
| 每股收益（稀释后） | $1.12 | $-0.63 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRICUI
| Q1 26 | $982.9M | — | ||
| Q4 25 | $962.7M | $540.7M | ||
| Q3 25 | $961.1M | $537.0M | ||
| Q2 25 | $966.0M | $548.9M | ||
| Q1 25 | $887.3M | $604.7M | ||
| Q4 24 | $848.1M | $629.8M | ||
| Q3 24 | $909.3M | $589.1M | ||
| Q2 24 | $910.1M | $596.5M |
净利润ATRICUI
| Q1 26 | $72.8M | — | ||
| Q4 25 | $74.3M | $-15.7M | ||
| Q3 25 | $127.9M | $-3.4M | ||
| Q2 25 | $111.7M | $35.3M | ||
| Q1 25 | $78.8M | $-15.5M | ||
| Q4 24 | $100.9M | $-23.8M | ||
| Q3 24 | $100.0M | $-33.0M | ||
| Q2 24 | $90.5M | $-21.4M |
毛利率ATRICUI
| Q1 26 | — | — | ||
| Q4 25 | — | 37.5% | ||
| Q3 25 | — | 37.4% | ||
| Q2 25 | — | 37.9% | ||
| Q1 25 | — | 34.7% | ||
| Q4 24 | — | 36.1% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.8% |
营业利润率ATRICUI
| Q1 26 | 10.9% | — | ||
| Q4 25 | 11.0% | 1.0% | ||
| Q3 25 | 14.2% | 2.6% | ||
| Q2 25 | 14.9% | 1.9% | ||
| Q1 25 | 12.8% | 2.1% | ||
| Q4 24 | 14.2% | 6.0% | ||
| Q3 24 | 15.2% | 1.4% | ||
| Q2 24 | 13.8% | 1.3% |
净利率ATRICUI
| Q1 26 | 7.4% | — | ||
| Q4 25 | 7.7% | -2.9% | ||
| Q3 25 | 13.3% | -0.6% | ||
| Q2 25 | 11.6% | 6.4% | ||
| Q1 25 | 8.9% | -2.6% | ||
| Q4 24 | 11.9% | -3.8% | ||
| Q3 24 | 11.0% | -5.6% | ||
| Q2 24 | 9.9% | -3.6% |
每股收益（稀释后）ATRICUI
| Q1 26 | $1.12 | — | ||
| Q4 25 | $1.13 | $-0.63 | ||
| Q3 25 | $1.92 | $-0.14 | ||
| Q2 25 | $1.67 | $1.43 | ||
| Q1 25 | $1.17 | $-0.63 | ||
| Q4 24 | $1.48 | $-0.97 | ||
| Q3 24 | $1.48 | $-1.35 | ||
| Q2 24 | $1.34 | $-0.88 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $229.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $2.1B |
| 总资产 | $5.1B | $4.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ATRICUI
| Q1 26 | $229.5M | — | ||
| Q4 25 | $409.5M | — | ||
| Q3 25 | $264.8M | — | ||
| Q2 25 | $169.8M | — | ||
| Q1 25 | $136.8M | — | ||
| Q4 24 | $226.2M | $308.6M | ||
| Q3 24 | $327.9M | $312.5M | ||
| Q2 24 | $223.9M | $302.6M |
总债务ATRICUI
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $546.0M | — | ||
| Q2 25 | $535.1M | — | ||
| Q1 25 | $561.2M | — | ||
| Q4 24 | $688.1M | — | ||
| Q3 24 | $822.7M | — | ||
| Q2 24 | $681.5M | — |
股东权益ATRICUI
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.7B | $2.1B | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $2.7B | $2.1B | ||
| Q1 25 | $2.5B | $2.0B | ||
| Q4 24 | $2.5B | $2.0B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.4B | $2.0B |
总资产ATRICUI
| Q1 26 | $5.1B | — | ||
| Q4 25 | $5.3B | $4.1B | ||
| Q3 25 | $5.1B | $4.1B | ||
| Q2 25 | $4.9B | $4.1B | ||
| Q1 25 | $4.5B | $4.2B | ||
| Q4 24 | $4.4B | $4.2B | ||
| Q3 24 | $4.6B | $4.3B | ||
| Q2 24 | $4.5B | $4.3B |
负债/权益比ATRICUI
| Q1 26 | — | — | ||
| Q4 25 | 0.43× | — | ||
| Q3 25 | 0.20× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.22× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.32× | — | ||
| Q2 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $60.6M |
| 自由现金流经营现金流 - 资本支出 | $53.3M | $36.0M |
| 自由现金流率自由现金流/营收 | 5.4% | 6.6% |
| 资本支出强度资本支出/营收 | 6.7% | 4.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $327.0M | $91.8M |
8季度趋势，按日历期对齐
经营现金流ATRICUI
| Q1 26 | — | — | ||
| Q4 25 | $183.7M | $60.6M | ||
| Q3 25 | $177.6M | $56.7M | ||
| Q2 25 | $126.0M | $11.2M | ||
| Q1 25 | $82.7M | $51.3M | ||
| Q4 24 | $178.2M | $40.2M | ||
| Q3 24 | $229.3M | $36.1M | ||
| Q2 24 | $143.6M | $82.0M |
自由现金流ATRICUI
| Q1 26 | $53.3M | — | ||
| Q4 25 | $96.9M | $36.0M | ||
| Q3 25 | $114.3M | $27.6M | ||
| Q2 25 | $62.5M | $-8.5M | ||
| Q1 25 | $25.9M | $36.7M | ||
| Q4 24 | $112.2M | $16.1M | ||
| Q3 24 | $162.7M | $16.2M | ||
| Q2 24 | $75.4M | $62.5M |
自由现金流率ATRICUI
| Q1 26 | 5.4% | — | ||
| Q4 25 | 10.1% | 6.6% | ||
| Q3 25 | 11.9% | 5.1% | ||
| Q2 25 | 6.5% | -1.5% | ||
| Q1 25 | 2.9% | 6.1% | ||
| Q4 24 | 13.2% | 2.6% | ||
| Q3 24 | 17.9% | 2.7% | ||
| Q2 24 | 8.3% | 10.5% |
资本支出强度ATRICUI
| Q1 26 | 6.7% | — | ||
| Q4 25 | 9.0% | 4.6% | ||
| Q3 25 | 6.6% | 5.4% | ||
| Q2 25 | 6.6% | 3.6% | ||
| Q1 25 | 6.4% | 2.4% | ||
| Q4 24 | 7.8% | 3.8% | ||
| Q3 24 | 7.3% | 3.4% | ||
| Q2 24 | 7.5% | 3.3% |
现金转化率ATRICUI
| Q1 26 | — | — | ||
| Q4 25 | 2.47× | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 1.13× | 0.32× | ||
| Q1 25 | 1.05× | — | ||
| Q4 24 | 1.77× | — | ||
| Q3 24 | 2.29× | — | ||
| Q2 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATR
暂无分部数据
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
